Gritstone Bio Gross Margin 2017-2024 | GRTSQ
Current and historical gross margin for Gritstone Bio (GRTSQ) over the last 10 years. The current gross profit margin for Gritstone Bio as of June 30, 2024 is %.
| Gritstone Bio Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2024-06-30 |
$0.02B |
$0.02B |
100.00% |
| 2024-03-31 |
$0.02B |
$0.02B |
100.00% |
| 2023-12-31 |
$0.02B |
$0.02B |
100.00% |
| 2023-09-30 |
$0.01B |
$0.01B |
100.00% |
| 2023-06-30 |
$0.01B |
$0.01B |
100.00% |
| 2023-03-31 |
$0.01B |
$0.01B |
100.00% |
| 2022-12-31 |
$0.02B |
$0.02B |
100.00% |
| 2022-09-30 |
$0.02B |
$0.02B |
100.00% |
| 2022-06-30 |
$0.02B |
$0.02B |
100.00% |
| 2022-03-31 |
$0.02B |
$0.02B |
100.00% |
| 2021-12-31 |
$0.05B |
$0.05B |
100.00% |
| 2021-09-30 |
$0.05B |
$0.05B |
100.00% |
| 2021-06-30 |
$0.05B |
$0.05B |
100.00% |
| 2021-03-31 |
$0.04B |
$0.04B |
100.00% |
| 2020-12-31 |
$0.00B |
$0.00B |
100.00% |
| 2020-09-30 |
$0.00B |
$0.00B |
100.00% |
| 2020-06-30 |
$0.00B |
$0.00B |
100.00% |
| 2020-03-31 |
$0.00B |
$0.00B |
100.00% |
| 2019-12-31 |
$0.00B |
$0.00B |
100.00% |
| 2019-09-30 |
$0.00B |
$0.00B |
100.00% |
| 2019-06-30 |
$0.00B |
$0.00B |
100.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
